Skip to main content

OTC Pain

  • With 0-16 season looming, Cleveland fans find pain-relieving support in Excedrin

    Warren, N.J.-based GSK Consumer Healthcare on Thursday announced its pain-relieving Excedrin brand will be a signature sponsor of Cleveland's upcoming (and unofficial) Perfect Season Parade slated for Jan. 6 in celebration of the team's historically bad 0-16 season.

  • GSK ready to kick the tires of any Pfizer OTC divestiture

    LONDON — If Pfizer follows through with its announcement last week to potentially place its consumer business up for sale, GlaxoSmithKline, presently the third-largest OTC seller in the U.S. marketplace, would certainly take a look at it, the company's CEO shared Wednesday morning.

  • Tylenol, new products impact pain

    NEW YORK — Johnson & Johnson’s McNeil Consumer Healthcare division has rebounded with the return of several product lines, including products under the powerhouse brand Tylenol, which had seen sales and market share erode in the wake of recalls in 2010.

  • Hisamitsu America innovates analgesics aisle with new Lidocaine Plus line

    FLORHAM PARK, N.J. — Hisamitsu America on Tuesday announced the Lidocaine Plus product line with the introduction of the Salonpas Lidocaine Plus Pain Relieving Cream and the Salonpas Lidocaine Plus Pain Relieving Liquid.

  • ‘For sale’ sign could soon hang over Pfizer’s consumer healthcare business

    NEW YORK — Pfizer on Tuesday might be putting its $3.4 billion consumer healthcare business on the sales block, noting that all scenarios would be considered during a strategic review of its options, which include a full or partial separation of the business from Pfizer through a spin-off, sale or other transaction.

    Of course, Pfizer may ultimately determine to retain the business, the company added.

  • Study: Topical analgesics may be one answer to the opioid crisis

    AUSTIN, Texas — Clarity Science, a division of Safe Harbor Compliance and Clinical Services, on Wednesday reported the results of the Institutional Review Board-approved Optimizing Patient Experience and Response to Topical Analgesics (OPERA) Study which evaluated patients with chronic pain who were treated with topical analgesics.

    Overall results, published in the Journal of Pain Research, suggest that topical treatments may provide an effective and safer treatment alternative to opioids and prescription NSAIDs for the management of chronic pain.

  • Oska Wellness adds two execs to C-suite, including COO and CFO

    CARLSBAD, Calif. — Oska Wellness on Tuesday announced two key additions to its executive leadership team with the hiring of Mike Regan as COO and Gary Acord as CFO.

    "I'm delighted to announce that Mike and Gary are joining our team," stated Greg Houlgate, CEO/president Oska Wellness. "We're building great momentum here at Oska Wellness.  Mike and Gary bring deep leadership experience at a time when we're focusing on its next phase of growth. This is an exciting time for the company."

X
This ad will auto-close in 10 seconds